📄 medicine

Global Trends in Cardiovascular Mortality and Major Cardiometabolic Risk Factors, 2000–2023: A Longitudinal Ecological Analysis of 204 Countries and Territories

This longitudinal ecological analysis of 204 countries from 2000 to 2023 reveals that while global cardiovascular mortality has declined, progress has stagnated since 2019, driven primarily by high systolic blood pressure and LDL cholesterol, with obesity acting as an upstream risk factor that operates almost entirely through downstream metabolic intermediaries.

Original authors: Khalid Mohammed Al-Dhayani

Published 2026-09-15

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Khalid Mohammed Al-Dhayani

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Heart disease remains the single greatest cause of death around the world, claiming the lives of millions every year. For decades, doctors and public health officials have known that certain habits and conditions make this risk much higher. High blood pressure, excess cholesterol in the blood, smoking, high blood sugar, and carrying extra weight are the primary drivers that damage the heart and blood vessels. While medical treatments have improved significantly, the sheer number of people dying from heart disease continues to rise, largely because the global population is growing and aging. The challenge for scientists is not just to count these deaths, but to understand exactly which of these risk factors are doing the most damage right now, and whether the world is making progress in controlling them.

A new study spanning 24 years offers a clear, global picture of this struggle. Researchers analyzed data from 204 countries and territories, tracking every year from 2000 to 2023. They looked at how many people died from heart disease in each nation, adjusted for the age of the population, and compared those numbers against the prevalence of the five major risk factors mentioned above. By using advanced statistical methods to account for differences in wealth, urbanization, and local health systems, the team was able to isolate the independent effect of each risk factor. This approach allowed them to see which factors were truly driving deaths on their own, separate from the others.

The most striking finding is that high blood pressure is the dominant force behind heart disease deaths globally. The study showed that for every increase in deaths caused by high blood pressure, there was a direct and powerful rise in overall heart disease mortality. This factor was more influential than any other, including high cholesterol, smoking, or high blood sugar. In fact, the researchers calculated that the global decline in heart disease deaths seen over the last two decades was largely due to better control of blood pressure. When blood pressure levels dropped in a country, heart disease deaths followed. High cholesterol and smoking also remained strong, independent causes of death, but their impact was smaller than that of blood pressure.

The study also clarified a confusing issue regarding body weight. For years, some observations suggested that being overweight might not be as dangerous as previously thought, or that it might even be protective in certain groups, a concept sometimes called the "obesity paradox." However, this large-scale analysis found that obesity itself does not directly cause heart disease deaths in the way blood pressure does. Instead, the data revealed that the danger of excess weight operates almost entirely through the other risk factors it creates. When a person carries extra weight, it frequently leads to high blood pressure, high cholesterol, and high blood sugar. The study showed that once these downstream effects were accounted for, the direct link between body weight and death disappeared. This means that while obesity is a critical upstream problem, its deadly impact is mediated through the metabolic conditions it triggers.

The timeline of the last 24 years tells a story of both progress and stagnation. Globally, the rate of heart disease deaths per person has fallen significantly, dropping from about 340 deaths per 100,000 people in 2000 to roughly 258 in 2023. This decline was driven by successful efforts to reduce smoking and lower cholesterol levels, alongside better blood pressure management. However, the progress hit a wall around 2019. After a brief pause in the downward trend during the pandemic years of 2020 and 2021, the rate of improvement slowed to a near standstill. Furthermore, while the average person is living longer, the absolute number of heart disease deaths continues to climb because the global population is larger and older.

The burden of these deaths is not shared equally. The study highlighted a stark divide between wealthy and poorer nations. Low-income countries face the highest rates of heart disease death, with rates nearly double those of high-income countries. This disparity is largely due to unequal access to healthcare, including screening for high blood pressure and affordable medications to control it. The data also showed that while some countries, particularly in Eastern Europe and Central Asia, achieved massive reductions in heart disease deaths over the last two decades, others saw their death rates rise or remain stubbornly high. Small island nations in the Pacific and countries in North Africa and the Middle East were identified as having some of the heaviest burdens.

Ultimately, the research confirms that the path to saving lives lies in a focused, multi-pronged approach. Because high blood pressure is the single biggest driver, universal efforts to detect and treat it are the most effective way to reduce global mortality. Controlling cholesterol and reducing smoking remain essential, but the fight against obesity must be viewed as a strategy to prevent the metabolic conditions that lead to death, rather than a direct intervention against heart disease itself. The data suggests that without renewed global commitment to these preventive measures, particularly in lower-income regions, the gains made over the last quarter-century will stall, and the total number of lives lost will continue to grow.

Technical Summary: Global Trends in Cardiovascular Mortality and Major Cardiometabolic Risk Factors, 2000–2023

Problem Statement
Cardiovascular disease (CVD) remains the leading cause of global mortality, with nearly three-quarters of deaths occurring in low- and middle-income countries (LMICs). While age-standardized CVD mortality rates have declined in many regions due to advances in prevention and treatment, the absolute number of deaths continues to rise due to population growth and aging. A critical gap exists in the literature regarding the simultaneous evaluation of multiple cardiometabolic risk pathways. Previous studies have largely relied on descriptive cross-sectional estimates or unadjusted attributable burden metrics (population attributable fractions). These approaches often fail to control for unobserved time-invariant country characteristics (e.g., institutional or health-system differences) and common global secular trends. Furthermore, the frequent clustering of risk factors within metabolic syndrome creates substantial collinearity, complicating the isolation of independent longitudinal associations for specific drivers such as systolic blood pressure (SBP), LDL cholesterol, fasting glucose, BMI, and smoking.

Methodology
This study employed a longitudinal ecological panel analysis covering 204 countries and territories over a 24-year period (2000–2023), yielding 4,896 balanced country-year observations. Data were harmonized from the Institute for Health Metrics and Evaluation (IHME) Global Burden of Disease (GBD) 2023 database and the World Bank Open Data repository.

Statistical Model: The primary analysis utilized a two-way fixed-effects (TWFE) panel regression model. This design incorporated both country fixed effects (to control for time-invariant unobserved heterogeneity) and calendar-year fixed effects (to account for global secular trends and common shocks).
Robust Inference: Recognizing that panel data often violates classical regression assumptions, the study addressed substantial serial correlation (Durbin–Watson statistic = 0.0989), heteroskedasticity (Breusch–Pagan LM statistic = 618.18), and cross-sectional dependence. Consequently, inference was based on Driscoll–Kraay robust standard errors, which provide valid covariance estimates under these conditions.
Variables: The dependent variable was the age-standardized CVD mortality rate (deaths per 100,000). Primary exposures were age-standardized mortality rates attributable to five risk factors: high SBP, high LDL cholesterol, high fasting plasma glucose, high BMI, and tobacco smoking. Covariates included GDP per capita (PPP) and urbanization percentage.
Sensitivity and Validation: The study conducted extensive robustness checks, including:
- Exclusion of COVID-19 pandemic years (2020–2021).
- Lagged analyses (1, 3, and 5-year lags) to assess temporal precedence.
- Nonlinearity testing via quadratic terms.
- Heterogeneity analysis by World Bank income groups and WHO regions.
- Influence diagnostics (Cook's distance) and leave-one-country-out (LOCO) sensitivity analyses.

Key Results

Temporal Trends: Global age-standardized CVD mortality declined from 340.2 ± 156.4 to 258.4 ± 132.1 deaths per 100,000 between 2000 and 2023. However, this decline stagnated post-2019, with annual percentage changes ranging from -1.31% to -0.03%. A transient increase occurred in 2020–2021, coinciding with the acute phase of the COVID-19 pandemic.
Independent Associations: In the primary TWFE model with Driscoll–Kraay errors:
- High SBP was the strongest independent predictor of CVD mortality ( $\beta$ = 1.129, $P < 0.001$ ).
- High LDL cholesterol ( $\beta$ = 0.622), smoking ( $\beta$ = 0.452), and high fasting glucose ( $\beta$ = 0.410) were also significantly positively associated with mortality ( $P < 0.001$ for all).
- High BMI was not directly associated with mortality after multivariable adjustment ( $\beta$ = 0.049, $P = 0.421$ ).
Mediation and Pathways: Analysis proved that 99.20% of the population-level impact of high BMI on CVD mortality is mediated through downstream metabolic intermediaries (SBP, lipids, glucose), rather than acting as a direct independent driver.
Decomposition of Decline: High SBP reduction accounted for 70.91% of the global modeled decline in CVD mortality, followed by LDL cholesterol (17.55%), smoking (8.25%), and fasting glucose (2.52%).
Heterogeneity: Significant heterogeneity was observed across income groups and WHO regions. For instance, the association between smoking and mortality was stronger in upper-middle-income countries and specific regions (AFRO, AMRO, WPRO), while LDL cholesterol showed a particularly strong association in the African Region.
Robustness: Results remained consistent across sensitivity analyses, including the exclusion of pandemic years and various lag structures. The "obesity paradox" (a negative association between BMI and mortality in simpler models) was attributed to omitted variable bias regarding global temporal trends; it disappeared when year fixed effects were included.

Significance and Claims
The paper claims that elevated SBP and cumulative LDL cholesterol are the primary independent drivers of global cardiovascular mortality. It posits that while obesity is a critical upstream determinant, its statistical effect is almost entirely mediated through downstream metabolic pathways. The study emphasizes that the stagnation in mortality decline post-2019 and the persistence of high burdens in LMICs and specific regions (e.g., Eastern Europe, Central Asia, Oceania) underscore the need for prioritized, multi-sectoral interventions.

The author concludes that sustained progress requires a dual focus: universal blood pressure control and lipid lowering, alongside multi-sectoral obesity prevention strategies that target the upstream drivers of metabolic intermediaries. The study reinforces the validity of using TWFE models with robust covariance estimation to disentangle complex, collinear risk pathways in global health data, offering a more nuanced understanding than traditional cross-sectional or unadjusted attributable burden analyses.

More like this